The clinical Phase Ib study of intravenous administered KAND567 has started and is planned to be completed during the third quarter of 2019. KAND567 has previously been shown to be well tolerated and to have good pharmacokinetic properties when administered orally to...
Read MoreKancera AB (Nasdaq First North: KAN) today announces that the European Society of Cardiology has selected Kancera's research for its "outstanding quality" which will result in an oral presentation as part of the session "Advances in Science - Emerging treatments in acute...
Read MoreThis is a translation of the press release in Swedish Stockholm 2019-05-02 Kancera AB (Nasdaq First North: KAN) today announces that the company is strengthening its project portfolio by nominating KAND145 as a new drug candidate. KAND145 is covered by a patent...
Read MoreThis is a translation of a press release in Swedish 2019-01-29 Kancera AB (Nasdaq First North: KAN) today announces that the results of a study of lymphoma patients' immune cells show that the Fractalkine system is activated in the cancers of chronic...
Read MoreThis is a translation from the Swedish press release 2019-01-28 Kancera AB (Nasdaq First North: KAN) today announces that intermediate goals have been achieved prior to the planned start of clinical trials with the drug candidate KAND567 to demonstrate reduced tissue damage...
Read MoreThis is a translation of a pressrelease in Swedish from December 3rd 2018. Kancera AB announced today that the company has entered into an Research and Option agreement with Grünenthal, a leading pharmaceutical company in pain research and management. As part of...
Read MoreHere follows a translation of a Swedish press release from November 23th 2018. Kancera announces that terms have been prepared for a shareholders' decision on investment in the company by Global Corporate Finance (GCF), New York. The investment, which covers a maximum...
Read MoreKancera AB today announced that the article entitled "Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination" has been published by researchers from Karolinska Institutet and Kancera AB in the journal Nature Communications1. The article documents the molecular mechanisms that give the small...
Read MoreKancera AB (publ) hereby reports on project activities and status for the preparation and implementation of a clinical study in cardiovascular inflammation associated with myocardial infarction. In the cancer area, it is announced that the research project funded by SWElife has been...
Read MoreThis is a translation of the Swedish press release published 2018-07-06. Kancera AB (publ) hereby announces that unique blockers (antagonists) of the Fractalkine system have been patented. Kancera intends to further develop a new drug candidate from the patented antagonists, and this...
Read More